Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | PNMT | P11086 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | QPCT | Q16769 | 2/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9917330 | 0.85 | ESR1 (0.42) | SLC6A2SLC6A3HTR2ASLC6A4HRH1 | |
| SCHEMBL562364 | 0.82 | SLC6A2 (0.55) | SLC6A2SLC6A3HTR2ASLC6A4HRH1 | |
| SCHEMBL12215710 | 0.82 | SLC6A2 (0.61) | SLC6A2SLC6A3HTR2ASLC6A4HRH1 | |
| SCHEMBL15546805 | 0.81 | ANO1 (0.41) | SLC6A2SLC6A3HTR2ASLC6A4HRH1 | |
| SCHEMBL13592379 | 0.81 | FDPS (0.41) | SLC6A2SLC6A3HTR2ASLC6A4HRH1 | |
| SCHEMBL13144963 | 0.80 | ANO1 (0.36) | SLC6A2SLC6A3HTR2ASLC6A4HRH1 | |
| SCHEMBL13509548 | 0.80 | PNMT (0.36) | TAAR1PNMTMAPTMAPK1ANO1 | |
| SCHEMBL1555419 | 0.79 | SLC6A2 (0.47) | SLC6A2SLC6A3HTR2ASLC6A4HRH1 | |
| SCHEMBL1720743 | 0.79 | IDO1 (0.58) | SLC6A2SLC6A3HTR2ASLC6A4HRH1 | |
| SCHEMBL16589323 | 0.79 | ANO1 (0.38) | PNMTMAPTMAPK1ANO1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2875001-B1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2019-01-09 | — | — | EP | disclosed |
| US-9434695-B2 | Nitrogenous heterocyclic derivatives and their application in drugs | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2016-09-06 | — | — | US | disclosed |
| EP-2875001-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | Sunshine Lake Pharma Co., Ltd. (CN) | 2015-05-27 | — | — | EP | disclosed |
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-03-26 | — | — | US | disclosed |
| WO-2014012360-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-01-23 | — | — | WO | disclosed |
| US-20120301552-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2012-11-29 | — | — | US | disclosed |
| US-20120301552-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2012-11-29 | — | — | US | disclosed |
| US-20120301552-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2012-11-29 | — | — | US | disclosed |
| CN-102365261-A | Process for producing carboxylic acid compound | JAPAN TOBACCO INC | 2012-02-29 | — | — | CN | disclosed |
| EP-2412697-A1 | PROCESS FOR PRODUCING CARBOXYLIC ACID COMPOUND | Japan Tobacco, Inc. (JP) | 2012-02-01 | — | — | EP | disclosed |
| WO-2009148052-A1 | SULFONAMIDE COMPOUND AND APPLICATION THEREOF | 旭化成ファーマ株式会社 (JP) | 2009-12-10 | — | — | WO | disclosed |
| EP-2120898-A1 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080255042-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080255042-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2008-10-16 | — | — | US | disclosed |
| WO-2008077009-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
| US-7304174-B2 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2007-12-04 | — | — | US | disclosed |
| US-7304174-B2 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2007-12-04 | — | — | US | disclosed |
| US-7304174-B2 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2007-12-04 | — | — | US | disclosed |
| EP-1619180-A1 | CaSR ANTAGONIST | JAPAN TOBACCO INC. (JP) | 2006-01-25 | — | — | EP | disclosed |
| US-20050032796-A1 | Compounds as for example, 2'-[1-[(2R)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-3-methylbiphenyl-4-carboxylic acid, having a calcium-sensing receptor antagonistic action; therapeutic drug for osteoporosis | JAPAN TOBACCO INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | TNNC1, TNNI3, IAPP | SLC6A2 1354/4885SLC6A3 1274/4885HTR2A 2764/4885 |
| US-20120301552-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | SLC6A2 1201/4885SLC6A3 1529/4885HTR2A 1085/4885 |
| US-20080255042-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | SLC6A2 1201/4885SLC6A3 1529/4885HTR2A 1085/4885 |
| US-20050032796-A1 | Compounds as for example, 2'-[1-[(2R)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-3-methylbiphenyl-4-carboxylic acid, having a calcium-sensing receptor antagonistic action; therapeutic drug for osteoporosis | CASR, CALCR, GRK2 | SLC6A2 1989/4885SLC6A3 2358/4885HTR2A 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.